BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

926

524372

ORCHPHARMA

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

ORCHID PHARMA LIMITED performance

Today’s low

Today’s high

₹ 795.00 ₹ 836.05
₹ 801.00

52 week low

52 week high

₹ 684.35 ₹ 1997.40
₹ 801.00

Open Price

₹ 835.00

Prev. Close

₹ 835.45

Volume (Shares)

36723.00

Total traded value

₹ 294.15

Upper Circuit

₹ 877.20

Lower Circuit

₹ 793.70

info

ORCHID PHARMA LIMITED Share Price Update

As of the latest trading session, ORCHID PHARMA LIMITED share price is currently at ₹ 801, which is down by ₹ -34.45 from its previous closing. Today, the stock has fluctuated between ₹ 795.00 and ₹ 836.05. Over the past year, ORCHID PHARMA LIMITED has achieved a return of -25.74 %. In the last month alone, the return has been 2.31 %. Read More...

ORCHID PHARMA LIMITED fundamentals


  • Market cap (Cr)

    4,062.60

  • P/E Ratio (TTM)

    36.54

  • Beta

    0.95

  • Book Value / share

    250.68

  • Return on equity

    3.15%

  • EPS (TTM)

    22.05

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    23.91

info icon alternate text
  • Market cap (Cr)

    4,052.20

  • P/E Ratio (TTM)

    36.54

  • Beta

    0.91

  • Book Value / share

    250.68

  • Return on equity

    3.15%

  • EPS (TTM)

    22.05

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    23.91

info icon alternate text

ORCHID PHARMA LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 217.34
Operating Expense 203.37
Net Profit 23.91
Net Profit Margin (%) 11.00
Earnings Per Share (EPS) 4.71
EBITDA 36.31
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 222.70
Operating Expense 205.04
Net Profit 25.63
Net Profit Margin (%) 11.50
Earnings Per Share (EPS) 5.05
EBITDA 37.56
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 244.41
Operating Expense 223.07
Net Profit 29.10
Net Profit Margin (%) 11.90
Earnings Per Share (EPS) 5.74
EBITDA 41.01
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 217.10
Operating Expense 200.03
Net Profit 33.19
Net Profit Margin (%) 15.28
Earnings Per Share (EPS) 6.86
EBITDA 41.81
Effective Tax Rate (%) -10.78
Particulars DEC 2023 (Values in Cr)
Revenue 220.59
Operating Expense 197.48
Net Profit 30.55
Net Profit Margin (%) 13.84
Earnings Per Share (EPS) 6.42
EBITDA 43.36
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 819.37
Operating Expense 758.24
Net Profit 94.75
Net Profit Margin (%) 11.56
Earnings Per Share (EPS) 19.59
EBITDA 141.07
Effective Tax Rate (%) -3.52
Particulars MAR 2023 (Values in Cr)
Revenue 665.90
Operating Expense 669.30
Net Profit 54.19
Net Profit Margin (%) 8.13
Earnings Per Share (EPS) 13.28
EBITDA 142.26
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 556.97
Operating Expense 618.75
Net Profit -4.81
Net Profit Margin (%) -0.86
Earnings Per Share (EPS) -1.18
EBITDA 66.25
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 450.70
Operating Expense 553.03
Net Profit -117.15
Net Profit Margin (%) -25.99
Earnings Per Share (EPS) -28.70
EBITDA 64.37
Effective Tax Rate (%) 0.00
Particulars MAR 2020 (Values in Cr)
Revenue 481.21
Operating Expense 593.94
Net Profit -149.84
Net Profit Margin (%) -31.13
Earnings Per Share (EPS) -16.87
EBITDA 33.61
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Book Value / Share 217.06
ROE % 3.02
ROCE % 3.20
Total Debt to Total Equity 0.25
EBITDA Margin 17.32
Particulars MAR 2023 (Values in Cr)
Book Value / Share 151.92
ROE % 0.29
ROCE % 1.47
Total Debt to Total Equity 0.45
EBITDA Margin 15.46
Particulars MAR 2022 (Values in Cr)
Book Value / Share 141.81
ROE % 0.06
ROCE % -1.10
Total Debt to Total Equity 0.55
EBITDA Margin 11.27
Particulars MAR 2021 (Values in Cr)
Book Value / Share 143.16
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.72
EBITDA Margin 9.91
Particulars MAR 2020 (Values in Cr)
Book Value / Share 187.67
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 61.28
EBITDA Margin -1.43
Particulars MAR 2024 (Values in Cr)
Book Value / Share 226.69
ROE % 3.15
ROCE % 3.33
Total Debt to Total Equity 0.24
EBITDA Margin 17.26
Particulars MAR 2023 (Values in Cr)
Book Value / Share 162.53
ROE % 0.81
ROCE % 2.34
Total Debt to Total Equity 0.43
EBITDA Margin 15.46
Particulars MAR 2022 (Values in Cr)
Book Value / Share 149.30
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.53
EBITDA Margin 12.06
Particulars MAR 2021 (Values in Cr)
Book Value / Share 150.13
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.69
EBITDA Margin 14.26
Particulars MAR 2020 (Values in Cr)
Book Value / Share 178.67
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 88.62
EBITDA Margin 7.39
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 266.56
Total Assets 1553.87
Total Liabilities 1553.87
Total Equity 1169.46
Share Outstanding 50719105
Price to Book Ratio 4.61
Return on Assets (%) 5.93
Return on Capital (%) 7.07
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 30.62
Total Assets 1225.20
Total Liabilities 1225.20
Total Equity 688.64
Share Outstanding 40816400
Price to Book Ratio 2.37
Return on Assets (%) 3.78
Return on Capital (%) 4.54
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 8.06
Total Assets 1110.56
Total Liabilities 1110.56
Total Equity 647.37
Share Outstanding 40816400
Price to Book Ratio 1.90
Return on Assets (%) -0.17
Return on Capital (%) -0.21
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 19.91
Total Assets 1237.25
Total Liabilities 1237.25
Total Equity 652.90
Share Outstanding 40816400
Price to Book Ratio 16.42
Return on Assets (%) -9.41
Return on Capital (%) -10.76
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 174.04
Total Assets 1459.90
Total Liabilities 1459.90
Total Equity 765.98
Share Outstanding 40816400
Price to Book Ratio 0.00
Return on Assets (%) -8.97
Return on Capital (%) -10.32
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 257.22
Total Assets 1552.20
Total Liabilities 1552.20
Total Equity 1218.31
Share Outstanding 50719105
Price to Book Ratio 4.61
Return on Assets (%) 6.10
Return on Capital (%) 7.01
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 22.33
Total Assets 1223.25
Total Liabilities 1223.25
Total Equity 731.96
Share Outstanding 40816400
Price to Book Ratio 2.37
Return on Assets (%) 4.42
Return on Capital (%) 5.1
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 4.20
Total Assets 1094.18
Total Liabilities 1094.18
Total Equity 677.95
Share Outstanding 40816400
Price to Book Ratio 1.90
Return on Assets (%) -0.43
Return on Capital (%) -0.51
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 18.96
Total Assets 1224.46
Total Liabilities 1224.46
Total Equity 681.33
Share Outstanding 40816400
Price to Book Ratio 16.42
Return on Assets (%) -9.56
Return on Capital (%) -10.33
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 172.31
Total Assets 1449.99
Total Liabilities 1449.99
Total Equity 797.82
Share Outstanding 40816400
Price to Book Ratio 0.00
Return on Assets (%) -10.33
Return on Capital (%) -11.51
Particulars MAR 2024 (Values in Cr)
Net Income 89.04
Cash from Operations 125.36
Cash from Investing -312.02
Cash from Financing 167.04
Net change in Cash -18.99
Free Cash Flow 190.17
Particulars MAR 2023 (Values in Cr)
Net Income 46.31
Cash from Operations 18.63
Cash from Investing -31.21
Cash from Financing 31.16
Net change in Cash 18.29
Free Cash Flow 103.54
Particulars MAR 2022 (Values in Cr)
Net Income -1.95
Cash from Operations 94.38
Cash from Investing 112.93
Cash from Financing -216.79
Net change in Cash -11.38
Free Cash Flow 108.78
Particulars MAR 2021 (Values in Cr)
Net Income -116.53
Cash from Operations 18.66
Cash from Investing 67.20
Cash from Financing -164.98
Net change in Cash -74.19
Free Cash Flow 19.26
Particulars MAR 2020 (Values in Cr)
Net Income -131.07
Cash from Operations 70.38
Cash from Investing 167.11
Cash from Financing -250.33
Net change in Cash -2.41
Free Cash Flow 74.62
Particulars MAR 2024 (Values in Cr)
Net Income 91.52
Cash from Operations 129.99
Cash from Investing -315.80
Cash from Financing 167.06
Net change in Cash -18.01
Free Cash Flow 185.14
Particulars MAR 2023 (Values in Cr)
Net Income 54.18
Cash from Operations 13.68
Cash from Investing -26.69
Cash from Financing 31.16
Net change in Cash 17.85
Free Cash Flow 98.24
Particulars MAR 2022 (Values in Cr)
Net Income -4.80
Cash from Operations 91.47
Cash from Investing 112.93
Cash from Financing -216.79
Net change in Cash -14.30
Free Cash Flow 105.87
Particulars MAR 2021 (Values in Cr)
Net Income -117.15
Cash from Operations 19.44
Cash from Investing 67.20
Cash from Financing -164.98
Net change in Cash -73.42
Free Cash Flow 20.04
Particulars MAR 2020 (Values in Cr)
Net Income -149.83
Cash from Operations 69.99
Cash from Investing 167.11
Cash from Financing -250.33
Net change in Cash -2.79
Free Cash Flow 74.23
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

ORCHID PHARMA LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
801.00 -4.12 redarrow
red-green-graph indicator
13 Bearish
3 Bullish
  • 5 Days 817.10
  • 26 Days 818.80
  • 10 Days 807.80
  • 50 Days 916.20
  • 12 Days 805.00
  • 100 Days 1086.00
  • 20 Days 806.20
  • 200 Days 1169.00
838.02 PIVOT

First Support

822.58

First Resistance

850.88

Second Support

809.72

Second Resistance

866.32

Third Support

794.28

Third Resistance

879.18

RSI

46.32

ADX

20.54

MACD

-13.86

Williams % R

-38.81

Commodity Channel Index (CCI)

54.44

Date

2025-04-30

Week

49995.00

Same Day

28707.00

Month

53752.00

1 Year

0.95

3 Year

0.78

Over 1 Month

2.31%

down

Over 1 Year

-25.74%

down

Over 3 Months

-42.56%

down

Over 3 Years

32.57%

down

Over 6 Months

-42.42%

down

Over 5 Years

113.63%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

ORCHID PHARMA LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
7.37%
Promoter Holdings
69.83%
FII
2.69%
DII
20.09%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Dhanuka Laboratories Limited 3.5419957E7 (69.84%) Shareholding of Promoter and Promoter Group
Quant Mutual Fund - Quant Small Cap Fund 3465947.0 (6.83%) Public Shareholding
Invesco India Equity Savings Fund And 6 Others Under Same Pan 2094548.0 (4.13%) Public Shareholding
Kotak Mahindra Trustee Co Ltd A/c Kotak Multicap Fund And 5 Others Under Same Pan 1594666.0 (3.14%) Public Shareholding
Jm Financial Mutual Fund - Jm Aggressive Hybrid Fund And 5 Others Under Same Pan 630734.0 (1.24%) Public Shareholding

News

Left Arrow
Right Arrow

ORCHID PHARMA LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
13 Sep 2012 3.0 Final 15 Sep 2012 Equity shares
19 Jul 2011 3.0 Final 21 Jul 2011 Equity shares
12 Jul 2010 10.0 Final 14 Jul 2010 Equity shares
17 Sep 2009 1.0 Final 19 Sep 2009 Equity shares
18 Sep 2008 3.0 Final 20 Sep 2008 Equity shares
12 Jul 2007 3.0 Final 15 Jul 2007 Equity shares
30 May 2006 0.0 Final 01 Jun 2006 Equity shares
13 Jul 2005 0.0 Interim 15 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
17 Sep 2005 15 Sep 2005 1:2
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
13 Sep 2012 3.0 Final 15 Sep 2012 Equity shares
19 Jul 2011 3.0 Final 21 Jul 2011 Equity shares
12 Jul 2010 10.0 Final 14 Jul 2010 Equity shares
17 Sep 2009 1.0 Final 19 Sep 2009 Equity shares
18 Sep 2008 3.0 Final 20 Sep 2008 Equity shares
12 Jul 2007 3.0 Final 15 Jul 2007 Equity shares
30 May 2006 0.0 Final 01 Jun 2006 Equity shares
13 Jul 2005 0.0 Interim 15 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
17 Sep 2005 15 Sep 2005 1:2
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

ORCHID PHARMA LIMITED Share Price

Orchid Pharma Limited, is one of the leading pharmaceutical companies in India head quartered in Chennai and involved in development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals with exports spanning over 40 countries. Orchid's world class manufacturing infrastructure include USFDA compliant API and Finished Dosage Form facilities at Chennai in India. The Company has dedicated state-of-art and GLP compliant R&D infrastructure for Process Research, Drug Discovery and Pharmaceutical Research at Chennai.

The Company has a portfolio of antibiotics, and veterinary products. Antibiotics are life-saving drugs used to ght infections. Different classes of antibiotics include Beta-lactam, Macrolide, Fluoroquinolone, Imidazoleetc. Cephalosporins are beta-lactam antimicrobials used to manage various infections from gram-positive and gramnegative bacteria. The ve generations of cephalosporins are useful against skin infections, urinary tract infections, lower respiratory tract infections, sexually transmitted diseases, surgical prophylaxis, and other infections like meningitis. Company is also engaged in manufacturing and export of general category nished dosage formulations and anti-infective nished dosage formulations through its formulation facilities.

The Company is a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well as in drug discovery, which was incorporated on 1st July 1992 as a 100% Export Oriented Unit (EOU). Orchid has two manufacturing sites for APIs (at Alathur near Chennai and at Aurangabad, near Mumbai) and three manufacturing sites for Dosage forms (at Irungattukottai and Alathur in Chennai), besides two R&D centres (at Sholinganallur and Irungattukottai, Chennai), all are state-of-the-art and have several international regulatory approvals, including the US FDA and UK MHRA. Orchid's API facilities are ISO certified for their quality, environmental management and operational health and safety systems. Orchid has a Joint Venture in China for manufacturing sterile APIs.

The Company commenced its operation in the year 1994, also in the same year; orchid had entered into an agreement with SBD Laboratories Italy for technology for keeping production in sterile condition. Orchid became the youngest Indian pharmaceutical company to be awarded the ISO 9002 certification in 1997. During the same year of 1997, the company made a tie-up with Technology Innovative Industry of Italy and also launched a range of new products in the steriles category. In 1998, Orchid, along with Cipla and Ranbaxy, had received approval from the Drug Controller of India (DCI) for the manufacture and export of sildenafil citrate, the main ingredient in Viagra, the drug developed by Pfizer to treat human male erectile dysfunction; by the way it had entered into the formulation market.

The Trophy for Excellent Performance in Exports was awarded to the company as part of the National Export Awards Programme for the year 1998-99. The initial range of products was launched by the company in 1999, which includes three injectable cephalosporin formulations and two coprescription analgesics of the NSAID category. These are Tax-O-bid (Cefotaxime injection), Cefogram (Ceftriaxone injection), Orzid (Ceftazidime injection), Orchidol (Tramadol tablets) and N-Ltd (Nimesulide dispersible tablets. In the year 2000, Orchid had signed a Memorandum of Understanding (MoU) with the Mumbai-based Ajanta Pharma Ltd to acquire the latter's bulk drugs manufacturing plant located at Aurangabad. During the year 2001, the company had issued foreign currency convertible bonds to International finance Corporation. Orchid had inked a 50:50 joint venture alliance pact with a California-based drug discovery research firm Bexel Biotechnology Inc in the year of 2002.

During the year 2003, the company had acquired Mano Pharmaceuticals for a consideration of Rs.26 crores and also in the same year received a formal approval from US Food and Drug Administration for Cephalaxin. Orchid signed a pact with Par Pharmaceuticals Inc in 2004 to market oral cephalosporin formulations in US market. In 2005, the company made pact with Alpharma Inc to market oral non-antibiotic formulations in US & European markets and also entered into agreement with STADA Pharmaceuticals, Inc (USA). In 2006, Orchid had signed a deal with Biovitrum in drug discovery field. The Company received approval from the US FDA for its ANDAs (abbreviated new drug application) for Cefdinir for capsules 300 mg and Cefdinir for oral suspension in July 2007.

In April 2008, Orchid formed a wholly owned subsidiary Orchid Pharma Japan K K (Orchid Japan) to foray into the high potential Japanese generics market and in August of the same year 2008 received approvals of its marketing authorization (MA) for piperacillin and tazobactam for injection for marketing in the EU countries. The Company made a strategic research collaboration and license agreement with Merck & Co in September 2008 focused on the discovery, development and commercialization of novel agents for the treatment of bacterial and fungal infections.

During 2009, Company undertook the development and manufacture of an anti-coagulant drug candidate initially discovered and developed through Phase I by Merck & Co., Inc., USA. Towards this end, it invested in Diakron Pharmaceuticals Inc., a US based drug discovery and development company which has an exclusive license agreement with Merck for the compound. The Company and Merck & Co., Inc, USA, established a strategic research collaboration and license agreement focused on the discovery, development
and commercialisation of novel agents for the treatment of bacterial and fungal infections. During 2008-09, the DCP application of Tazobactum Piperacillin was successfully completed and the product was launched in the EU market in distribution partnership with Hospira. The Company accelerated Orchid's proprietary drug discovery business by developing several additional hits and leads in the therapeutic areas of inflammation, oncology, diabetes and anti-infectives.

The Company sold/ transferred Generic Injectable Formulations Business, including the facility situated at Irungattukottai near Chennai to Hospira Healthcare India Private Limited, a subsidiary of Hospira Inc., USA based on the approval from various Government agencies and the shareholders. The business transfer proposal was built on the existing product development and commercialisation relationship between Hospira and Orchid, which covered several product-market segments which completed in 2009-10.

During 2010-11, Company acquired Karalex Pharma, LLC, a US based generic marketing and sales services Company headquartered in
New Jersey through Company's step down subsidiary Orchid Pharma Inc. The Company formed a new subsidiary namely Orchid Pharma, Inc., in the USA. It increased stake in Diakron Pharmaceuticals Inc. which holds 64.55% in the Company. Orchid
Pharmaceuticals (South Africa) Pty Ltd. was incorporated as a wholly owned subsidiary of the Company to register and market Company's products in South Africa.

During 2011-12, Orchid Research Laboratories Limited (ORLL) a wholly-owned subsidiary was merged with Company effective from April 01, 2010 i.e. the Appointed Date' which was sanctioned by The Hon'ble High Court of Madras and the Scheme of Amalgamation became effective with the Registrar of Companies, Chennai, Tamil Nadu from March 30, 2012. Bexel became a 100% subsidiary of Company upon amalgamation of Orchid Research Laboratories Limited with Company. The Company increased its stake in Diakron
Pharmaceuticals Inc., and holds 76.4% in the Company in 2011-12.

During the year 2012-13, company incorporated Orchid Pharma Singapore Private Limited a wholly owned subsidiary in Singapore to deal in pharmaceuticals products. The Business Transfer Agreement (BTA) with Hospira for the transfer of Aurangabad Penems and Penicillin Plant and R&D facility at Shozhanganallur was completed on July 4, 2014. In January 2017, Company launched a new product, 'Rasagiline' in the US market.

According to the Resolution Plan approved by the Hon'ble National Company Law Tribunal (NCLT) has, by its Order dated June 27, 2019 and the order of the Hon'ble Supreme Court vide its Order dated February 28, 2020, Dhanuka Laboratories Limited (DLL), the successful Resolution Applicant, implemented the Resolution Plan on March 31, 2020. DLL infused the funds as per the terms of the resolution plan through a special purpose vehicle, Dhanuka Pharmaceuticals Private Limited. The special purpose vehicle was later on merged with the Company as per the terms of the approved resolution plan. Thus the Company became a subsidiary of M/s Dhanuka Laboratories Limited with effect from March 31, 2020.

The Company subscribed to 2,600 equity shares of Rs.10/- each constituting 26% of paid up equity share capital of M/s OrBion Pharmaceuticals Private Limited during FY 2021-2022 and consequently, the Company became an Associate of Company. Orchid Bio-Pharma limited was incorporated as Indian Wholly owned Subsidiary (WoS) of the Company on March 24, 2022.

The Company and M/s. Dhanuka Laboratories Limited got amalgamated through the Scheme of Arrangement in 2023-24.

Parent organization Indian Private
NSE symbol ORCHPHARMA
Founded 1992
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Orchid Pharma Ltd?

Answer Field

The share price of Orchid Pharma Ltd for NSE is ₹ 801 and for BSE is ₹ 798.95.

What is the Market Cap of Orchid Pharma Ltd?

Answer Field

The market cap of Orchid Pharma Ltd for NSE is ₹ 40,62.60 Cr. and for BSE is ₹ 40,52.20 Cr. as of now.

What is the 52 Week High and Low of Orchid Pharma Ltd?

Answer Field

The 52 Week High and Low of Orchid Pharma Ltd for NSE is ₹ 1997.40 and ₹ 684.35 and for BSE is ₹ 1998.00 and ₹ 670.05.

How to Buy Orchid Pharma Ltd share?

Answer Field

You can trade in Orchid Pharma Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Orchid Pharma Ltd?

Answer Field

The 1 year returns on the stock has been -25.74%.

What is the Current Share Price of Orchid Pharma Ltd?

Answer Field

Orchid Pharma Ltd share price is for NSE ₹ 801 & for BSE ₹ 798.95 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Orchid Pharma Ltd Share?

Answer Field

The market cap of Orchid Pharma Ltd for NSE ₹ 40,62.60 & for BSE ₹ 40,52.20 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Orchid Pharma Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Orchid Pharma Ltd share is 36.54.

What is the PB ratio of Orchid Pharma Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Orchid Pharma Ltd share is 250.68.

How to Buy Orchid Pharma Ltd Share?

Answer Field

You can trade in Orchid Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Orchid Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Orchid Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Orchid Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|